Expert Insights Into the Management of MPNs : Episode 12
Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF
Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.
EP: 1.An Overview of Myeloproliferative Neoplasms (MPNs)
EP: 2.Risk Assessment for Patients with Polycythemia Vera (PV)
EP: 3.Current Treatment Landscape for Patients With PV
EP: 4.Selecting a Frontline Therapy for Patients With PV
EP: 5.Ruxolitinib for the Management of PV
EP: 6.Ropeginterferon alfa-2b for the Treatment of PV
EP: 7.Reviewing the Types of Myelofibrosis
EP: 8.The Role of Transplant in the Treatment of Patients With MF
EP: 9.COMFORT-I and COMFORT-II Data Review
EP: 10.Pacritinib and Fedratinib for the Treatment of MF
EP: 11.Sequencing Therapies in Patients with MF
Now Viewing
EP: 12.Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF
EP: 13.Symptom Monitoring in Patients with MF
EP: 14.Exploring the Future of MF Treatment
Related Videos
Related Content
